EP2694672B1 - Method for the lysis of cells and pcr amplification - Google Patents
Method for the lysis of cells and pcr amplification Download PDFInfo
- Publication number
- EP2694672B1 EP2694672B1 EP12704033.5A EP12704033A EP2694672B1 EP 2694672 B1 EP2694672 B1 EP 2694672B1 EP 12704033 A EP12704033 A EP 12704033A EP 2694672 B1 EP2694672 B1 EP 2694672B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- dna
- pcr
- photolysis
- method step
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 65
- 230000009089 cytolysis Effects 0.000 title claims description 20
- 238000012408 PCR amplification Methods 0.000 title claims description 11
- 238000004458 analytical method Methods 0.000 claims description 20
- 238000006303 photolysis reaction Methods 0.000 claims description 16
- 230000015843 photosynthesis, light reaction Effects 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000009396 hybridization Methods 0.000 claims description 8
- 238000010186 staining Methods 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 241000192125 Firmicutes Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 239000001226 triphosphate Substances 0.000 claims description 2
- 235000011178 triphosphate Nutrition 0.000 claims description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 60
- 108020004414 DNA Proteins 0.000 description 48
- 208000003443 Unconsciousness Diseases 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 238000000746 purification Methods 0.000 description 10
- 239000000975 dye Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000006037 cell lysis Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000005255 gram-positive cell Anatomy 0.000 description 5
- 238000005496 tempering Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- 210000005256 gram-negative cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 150000004706 metal oxides Chemical class 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 238000002032 lab-on-a-chip Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- IHZXTIBMKNSJCJ-UHFFFAOYSA-N 3-{[(4-{[4-(dimethylamino)phenyl](4-{ethyl[(3-sulfophenyl)methyl]amino}phenyl)methylidene}cyclohexa-2,5-dien-1-ylidene)(ethyl)azaniumyl]methyl}benzene-1-sulfonate Chemical compound C=1C=C(C(=C2C=CC(C=C2)=[N+](C)C)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S(O)(=O)=O)=C1 IHZXTIBMKNSJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001106476 Violaceae Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- IDAQSADEMXDTKN-UHFFFAOYSA-L ethyl green Chemical compound [Cl-].[Br-].C1=CC([N+](C)(C)CC)=CC=C1C(C=1C=CC(=CC=1)N(C)C)=C1C=CC(=[N+](C)C)C=C1 IDAQSADEMXDTKN-UHFFFAOYSA-L 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000004961 triphenylmethanes Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502753—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0877—Flow chambers
Definitions
- the invention relates to a method for the lysis of cells and PCR amplification of the DNA of the cells.
- MRSA Methicillin-resistant Staphylococcus aureus
- pneumonia Sepsis
- tuberculosis and fluoroquinolone resistance in Escherichia coli
- fluoroquinolone resistance in Escherichia coli are some examples.
- these resistances are usually determined based on cell culture.
- the cell culture-based determination of resistance is a relatively lengthy process, since the culture and evaluation 2-3 days must be scheduled.
- DNA analysis of the bacterial DNA resistances can be determined significantly faster. However, the DNA of the cells must be amplified, i. be increased.
- Gram-negative cells the PCR works even if cell material is used directly after a prolonged first high-temperature step without purification, as at temperatures near the boiling point the cells are destroyed and DNA is released.
- this does not work with Gram-positive cells, which have a particularly resistant cell membrane.
- Gram-positive bacteria die during this heating, the DNA contained in them can not leave the bacterial envelope and can not be duplicated accordingly.
- a photolysis with a laser describes the EP 4342914 A1 .
- a cell-containing solution is first placed on a metal oxide carrier, wherein the metal oxide binds cells. Subsequently, the metal oxide is irradiated with the laser, destroying the cell walls and releasing DNA. Subsequently, unbound cell components are washed out in a purification step. These procedures require a lot of effort and handling before the PCR can begin.
- EP 1797956 A1 shows a microfluidic device for the concentration and lysis of cells or viruses and an associated method, the microfluidic device comprising: a reaction chamber in which magnetic beads can be accommodated, comprising a plurality of electrodes 20, 20 'for generating a nonuniform electric field, a vibrating member for moving the magnetic beads in the chamber, and a laser source for emitting a laser beam onto the magnetic beads in the reaction chamber.
- US 2003/096429 A1 shows a method for determining laser parameters for cell lysis, exposing the cells from a sub-sample of a sample to the laser light. At least one parameter of the laser is varied and damage to intracellular molecules of the subsamples of the sample becomes at the parameters so different measured. At least one of the parameters is determined based on the measured damage.
- US 2008/171366 A1 discloses a method and apparatus for disrupting cells and amplifying nucleic acids using gold nanorods which are laser irradiated to disrupt the cells.
- the invention can be easily transferred to the current biochemical assay.
- the invention also makes it possible to amplify Gram-positive bacteria or other cells which are difficult to lyse, such as fungi or spores, which makes possible a platform with applications for urinary tract infections, MRSA, pneumonia, sepsis, mycoses, etc.
- a laser scanner for scanning a sample can be conveniently realized with a micromirror in a very small construction and allows a compact analyzer.
- the laser lysis can be realized compactly with standardized components for optics, scanners and lasers with a considerably lower outlay than lysis devices according to the prior art.
- the invention makes possible a Lab-on-a-Chip (LOC for short) as ⁇ TAS (Micro Total Analysis System), since the sequence of the processing and amplification steps before the detection is simplified compared to the prior art and an automatable to be transferred into a biochip Simplification of the Protocol.
- LOC Lab-on-a-Chip
- TAS Micro Total Analysis System
- Fig. 1 1 shows an LOC 10 in an analysis device 30 for lysis of cells and PCR amplification, both for DNA evaluation with an array 18.
- the LOC 10 has a rigid, flat substrate 11 with a fluidic network 12 in the substrate 11.
- To the fluidic network 12 include microchannels 13 shown by way of example, valves 14 and chamber 15, and a multi-function chamber 19 with a filter 16, in which inter alia, a PCR takes place, and an array chamber 17 with the array 18.
- the filter 16 contains here as a filter medium a silica Pad and is temperature controlled by a first external temperature control element 43 under the substrate 11.
- the filter 16 fills a flow-through cross-section of the multi-function chamber 19 fully.
- the array chamber 17 can be tempered via a second tempering element 44 under the substrate 11.
- Elements of the fluidic network 12 can also run in the interior of the LOC 10 and are liquid-tight at the top with a membrane or film, not shown.
- the actuators for the operation of the fluidic network 12 and a fluidic interface to the analyzer 30 are not shown.
- the analyzer 30 includes a photolysis light source 31 for irradiating the filter 16 and a controller 32 for performing lysis by irradiating the filter.
- the photolysis light source 31 in this embodiment has a laser 33, a beam expander 34, a micromirror 35 and a lens 36.
- a light beam 37 leaving the laser 33 passes via the beam expander 34 to the micromirror 35 and is deflected there and continues to pass through the lens 36 to the filter 16.
- the micromirror 35 is a controllable micromirror, with which the laser light beam 37 forms the filter 16 focused and raster-shaped according to the beam diameter can sweep.
- the analyzer 30 further includes a camera 39 and an array illumination lightwave 40, each directed to the array 18.
- the controller 32 is connected via electrical control lines 38 to the laser 33, the micromirror 35, the camera 39, the array illumination lightwave 40, the micromirror 35 and the tempering elements 43 and 44.
- the analysis device 30 further has a mechanical interface (not shown) with the LOC 10 with which the LOC 10 is positioned in the analysis device 30 in a defined manner. Due to the defined positioning of the filter 16 and the array 18 in the LOC, LOCs are interchangeable in the analyzer 30 without re-optical adjustment.
- the photolysis light source 31 is directed to the position of the filter 16 and the camera 39 is directed to the position of the array 18, here in the array chamber 17.
- the filter 16 is arranged above the first external tempering element 43, and the array chamber 17 is arranged above the second tempering 44.
- tempering Peltier elements micro-hotplates or convective heating / cooling elements, optionally electrical resistors, can also be used in combination.
- the mechanical interface allows a suitable heat transfer.
- the controller 32 controls the flow of the assay protocol on the LOC 10.
- the fluidic network 12 is controlled via the fluidic interface. Temperatures and temperature changes are controlled by the temperature control elements 43 and 44.
- the detection is carried out with an array / biochip and is checked by means of the one fluorescence exciting an array illumination light wave 40 and the fluorescent light observing camera 39, alternatively another (not shown) photometer.
- the evaluation of a DNA analysis is carried out by the observation at which positions fluorescence takes place on an array 18, with the camera 39.
- the LOC 10 for lysis of cells and PCR amplification has a common, filter 16 having a multi-function chamber 19 for cell accumulation, cell staining, cell lysis and PCR.
- Fig. 2 Figure 4 shows an LOC 46 in an analysis device 47 for cell lysis and PCR amplification, both for DNA evaluation. From Fig. 1 known elements again have the same reference numerals.
- the fluorescent dyes used in the real-time PCR are excited by a light source 41 and a detector 42, the resulting fluorescence radiation , possibly at different wavelengths, observed.
- an array chamber is not required.
- the DNA of the cells is present in sufficient quantity for DNA examinations.
- the method is suitable for Gram-negative and Gram-positive cells.
- a cell-containing liquid usually body fluid such as urine, sputum, serum, plasma, smears, BAL (bronchoalveolar lavage), etc. via a filter medium, in order to position the cells on the filter Fig. 1 and 2 over the filter 16 silica fiber pad, pumped.
- the cells are separated and washed with a few 100 ul buffer.
- the filter is filled with the PCR treatment solution, the so-called master mix.
- This PCR treatment solution consists of a mixture of DNTPs (deoxynucleotide triphosphates), primers, polymerase and buffer. Further, in the mixture, a substance for blocking the filter surface is contained, e.g. BSA (Bovine serum albumin), PEG (Polyethylene glycol), PPG (Polypropylene glycol). It is also possible to add the substances required only in process step e) only after process step d).
- the photolysis of the cells in process step d) is preferably carried out by means of laser lysis.
- the filter on which the stained cells are located is irradiated with a commercially available laser.
- the laser beam is preferably focused and guided with a micromirror on the filter, wherein as far as possible the entire filter surface is swept over completely with the laser beam.
- the filter can also be irradiated with high-energy LEDs, flash lamps or focused light sources with high energy density.
- the decisive factor is that the bacteria absorb as much light as possible, whereas the matrix and the surrounding liquid should absorb as little energy as possible.
- the light used for photolysis substantially in a wavelength range which is strongly absorbed by the colored cells but weakly absorbed by water.
- the color of the stained cells is determined by the dye, but may be different from the color of the dye.
- the wavelength or wavelengths of the photolysis light are matched to the color of the stained cells, so that the absorption coefficient of the stained cell is a multiple of the absorption coefficient of a fluid or a stationary phase of a buffer medium present around the cells, usually water.
- a multiple may be, for example, at least the factor 2.5, for example 10.
- a high energy intake of the fluid or the stationary phase would result in a strong, poorly controlled increase in temperature, which may lead to inactivation of the polymerase, evaporation of the liquid medium and bursting of the LOCs.
- the photolysis light source advantageously has a Wavelength in the visible region which is complementary to the color of the stained cells is, for example, 532 nm in the case of red staining of the cells with methylene blue, so that the absorption by the stained bacteria is as high as possible.
- the filter is subjected to the usual thermal cycles for the PCR. At these temperature cycles, the DNA is amplified as described above. Now the DNA of the cells is in sufficient quantity for DNA examinations.
- the method is suitable for Gram-negative and Gram-positive cells.
- the DNA can be eluted from the filter element.
- amplifications including isotherms, are also possible, for example NASBA (Nucleic Acid Sequence Based Amplification).
- the hybridization buffer may comprise a buffer system and a salt to increase a salt concentration.
- the method according to the invention can be easily transferred both to the filter PCR and to a fully integrated LOC.
- the DNA of the cells is present in sufficient quantity for DNA examinations.
- the method is suitable for Gram-negative and Gram-positive cells.
- the method steps of the same name correspond to those of the description of FIG Fig. 3 known method steps, taking into account the following differences.
- the DNA of the cells is then purified in process step d1). This purification can be accomplished by one or more washes in which cell components other than DNA are removed. Because of the liquid exchange associated with the cleaning, the PCR treatment solution is added only after the purification - process step c) thus takes place after process step d1).
Description
Die Erfindung betrifft ein Verfahren zur Lyse von Zellen und PCR-Amplifikation der DNA der Zellen.The invention relates to a method for the lysis of cells and PCR amplification of the DNA of the cells.
In der Diagnostik von Infektionskrankheiten gewinnt der Nachweis von Antibiotika-Resistenzen aufgrund zunehmender Verbreitung dieser Resistenzen eine immer größere Bedeutung. Methicillin-resistant Staphylococcus aureus (MRSA), Lungenentzündung (Pneumonie), Sepsis, Tuberkulose, und Fluorchinolonresistenz bei Escherichia coli seien als einige Beispiele genannt. In der herkömmlichen Diagnostik werden diese Resistenzen meist zellkulturbasiert ermittelt. Die zellkulturbasierte Resistenzbestimmung ist jedoch ein relativ langwieriges Verfahren, da für die Kultur und Auswertung 2-3 Tage angesetzt werden müssen. Mittels DNA-Analyse der Bakterien-DNA lassen sich Resistenzen deutlich schneller bestimmen. Dabei muss jedoch die DNA der Zellen amplifiziert, d.h. vermehrt werden.In the diagnosis of infectious diseases, the detection of antibiotic resistance is becoming increasingly important due to the increasing prevalence of these resistances. Methicillin-resistant Staphylococcus aureus (MRSA), pneumonia, sepsis, tuberculosis, and fluoroquinolone resistance in Escherichia coli are some examples. In conventional diagnostics, these resistances are usually determined based on cell culture. The cell culture-based determination of resistance, however, is a relatively lengthy process, since the culture and evaluation 2-3 days must be scheduled. By means of DNA analysis of the bacterial DNA, resistances can be determined significantly faster. However, the DNA of the cells must be amplified, i. be increased.
Die Polymerase-Chain-Reaction (PCR, Polymerase-Kettenreaktion) wurde Mitte der 80-er Jahre entdeckt und wird für die DNA-Amplifizierung heute flächendeckend in Diagnostik, Forschung und Forensik eingesetzt. Dabei wird eine temperaturstabile DNA-Polymerase zu der zu amplifizierenden DNA zugegeben und ein Temperaturzyklus bestehend aus
- Denaturierung, d.h. Aufspaltung DNA in Einzelstränge, bei ca. 95 °C;
- Primeranlagerung bei ca. 55 °C; und
- Elongation. d.h. Synthese der neuen DNA, bei ca. 72 °C;
- Denaturation, ie splitting DNA into single strands, at about 95 ° C;
- Primer attachment at about 55 ° C; and
- Elongation. ie synthesis of the new DNA, at about 72 ° C;
Bei Gram-negativen Zellen funktioniert die PCR auch wenn nach einem verlängerten ersten Hochtemperaturschritt direkt ohne Reinigung Zellmaterial eingesetzt wird, da bei Temperaturen nahe dem Siedepunkt die Zellen zerstört werden und DNA freigesetzt wird. Dies funktioniert jedoch nicht bei Gram-positiven Zellen, die eine besonders widerstandsfähige Zellmembran besitzen. Gram-positive Bakterien sterben zwar bei dieser Erhitzung ab, die in ihnen enthaltene DNA kann jedoch die Bakterienhülle nicht verlassen und entsprechend nicht vervielfältigt werden.In Gram-negative cells, the PCR works even if cell material is used directly after a prolonged first high-temperature step without purification, as at temperatures near the boiling point the cells are destroyed and DNA is released. However, this does not work with Gram-positive cells, which have a particularly resistant cell membrane. Although Gram-positive bacteria die during this heating, the DNA contained in them can not leave the bacterial envelope and can not be duplicated accordingly.
Für die Lyse Gram-positiver Zellen werden derzeit verschiedene Verfahren eingesetzt, darunter Enzymatische Lyse, Ultraschall-Lyse und Elektroporation. Eine Photolyse mit einem Laser beschreibt die
Mit dem erfindungsgemäßen Verfahren lassen sich mit im Vergleich zum Stand der Technik geringem Aufwand Zellen, insbesondere Bakterien, Pilze, Viren, Blutzellen und Zellverbände in einem Filter ohne Enzyme lysieren. Dies ist gegebenenfalls auch unter Vermeidung einer Aufreinigung nach der Lyse möglich.With the method according to the invention, it is possible to lyse cells, in particular bacteria, fungi, viruses, blood cells and cell aggregates in a filter without enzymes, in comparison to the prior art. This is possibly also possible while avoiding purification after lysis.
Die Erfindung lässt sich einfach auf den aktuellen biochemischen Assay übertragen.The invention can be easily transferred to the current biochemical assay.
Die Erfindung ermöglicht es, auch Gram-positive Keime oder andere schwer lysierbare Zellen wie Pilze oder Sporen zu amplifizieren, was erst eine Plattform mit Applikationen für Harnwegsinfekte, MRSA, Pneumonie, Sepsis, Mycosen, usw. ermöglicht.The invention also makes it possible to amplify Gram-positive bacteria or other cells which are difficult to lyse, such as fungi or spores, which makes possible a platform with applications for urinary tract infections, MRSA, pneumonia, sepsis, mycoses, etc.
Ein Laser-Scanner zum Abscannen einer Probe kann günstig mit einem Mikrospiegel in sehr kleiner Bauweise realisiert werden und ermöglicht ein kompaktes Analysegerät. Die Laserlyse lässt sich mit standardisierten Bauelementen für Optik, Scanner und Laser kompakt realisieren mit einem wesentlich geringeren Aufwand als Lyseeinrichtungen nach dem Stand der Technik.A laser scanner for scanning a sample can be conveniently realized with a micromirror in a very small construction and allows a compact analyzer. The laser lysis can be realized compactly with standardized components for optics, scanners and lasers with a considerably lower outlay than lysis devices according to the prior art.
Gegenüber enzymatischen / chemischen Lysen ist die deutliche Vereinfachung des Assays ausschlaggebend.Compared to enzymatic / chemical lyses, the clear simplification of the assay is crucial.
Gegenüber Ultraschalllysen ist neben dem Aufwand für den Generator die einfachere Auslegung und Abstimmung des Chips entscheidend.Opposite Ultraschalllysen is in addition to the effort for the generator simpler design and tuning of the chip crucial.
Die Erfindung ermöglicht ein Lab-on-a-Chip (kurz LOC) als µTAS (Micro Total Analysis System), da der Ablauf der Aufarbeitungs- und Amplifizierungsschritte vor der Detektion gegenüber dem Stand der Technik vereinfacht ist und eine in einen Biochip übertragbare, automatisierungsfähige Vereinfachung des Protokolls geschaffen worden ist.The invention makes possible a Lab-on-a-Chip (LOC for short) as μTAS (Micro Total Analysis System), since the sequence of the processing and amplification steps before the detection is simplified compared to the prior art and an automatable to be transferred into a biochip Simplification of the Protocol.
-
Fig. 1 zeigt eine schematische Darstellung eines LOC in einer Analysevorrichtung zur Lyse von Zellen und PCR-Amplifikation.Fig. 1 shows a schematic representation of an LOC in an analysis device for lysis of cells and PCR amplification. -
Fig. 2 zeigt eine schematische Darstellung eines LOC in einer Analysevorrichtung zur Lyse von Zellen und PCR-Amplifikation.Fig. 2 shows a schematic representation of an LOC in an analysis device for lysis of cells and PCR amplification. -
Fig. 3 zeigt ein Flussdiagramm des Verfahrens zur Lyse von Zellen und PCR-Amplifikation gemäß einer Ausführungsform der vorliegenden Erfindung ohne Reinigungsschritt.Fig. 3 Figure 12 shows a flow chart of the method for lysis of cells and PCR amplification according to an embodiment of the present invention without purification step. -
Fig. 4 zeigt ein Flussdiagramm des Verfahrens zur Lyse von Zellen und PCR-Amplifikation gemäß einer weiteren Ausführungsform der vorliegenden Erfindung mit Reinigungsschritt.Fig. 4 Fig. 10 shows a flow chart of the method for lysis of cells and PCR amplification according to another embodiment of the present invention with purification step.
gehören beispielhaft gezeigte Mikrokanäle 13, Ventile 14 und Kammer 15, sowie eine Multifunktionskammer 19 mit einem Filter 16, in der unter anderem eine PCR stattfindet, und eine Array-Kammer 17 mit dem Array 18. Der Filter 16 enthält hier als Filtermedium ein Silica-Pad und ist über ein erstes externes Temperierelement 43 unter dem Substrat 11 temperierbar. Der Filter 16 füllt einen durchströmten Querschnitt der Multifunktionskammer 19 voll aus. Die Array-Kammer 17 ist über ein zweites Temperierelement 44 unter dem Substrat 11 temperierbar. Elemente des fluidischen Netzwerks 12 können auch im Inneren des LOC 10 verlaufen und sind an der Oberseite mit einer nicht gezeigten Membran bzw. Folie flüssigkeitsdicht abgeschlossen. Die Betätigungselemente für den Betrieb des fluidischen Netzwerks 12 und eine fluidische Schnittstelle zur Analysevorrichtung 30 sind nicht dargestellt.
include
Die Analysevorrichtung 30 weist eine Photolyse-Lichtquelle 31 zur Bestrahlung des Filters 16 und eine Steuerung 32 zur Durchführung der Lyse mittels Bestrahlung des Filters auf. Die Photolyse-Lichtquelle 31 weist in dieser Ausführungsform einen Laser 33, einen Strahlaufweiter 34, einen Mikrospiegel 35 und eine Linse 36 auf. Ein den Laser 33 verlassender Lichtstrahl 37 verläuft über den Strahlaufweiter 34 zum Mikrospiegel 35 und wird dort umgelenkt und verläuft weiter über die Linse 36 zum Filter 16. In dieser Ausführungsform ist der Mikrospiegel 35 ein steuerbarer Mikrospiegel, mit dem der Laser-Lichtstrahl 37 den Filter 16 fokussiert und entsprechend dem Strahldurchmesser rasterförmig überstreichen kann. Die Analysevorrichtung 30 weist weiterhin eine Kamera 39 und eine Array-Beleuchtungs-Lichtwelle 40 auf, die jeweils auf das Array 18 gerichtet sind.The
Die Steuerung 32 ist über elektrische Steuerleitungen 38 mit dem Laser 33, dem Mikrospiegel 35, der Kamera 39, der Array-Beleuchtungs-Lichtwelle 40, dem Mikrospiegel 35 und den Temperierelementen 43 und 44 verbunden.The
Die Analysevorrichtung 30 weist weiterhin eine nicht gezeigte mechanische Schnittstelle mit dem LOC 10 auf, mit der das LOC 10 in der Analysevorrichtung 30 definiert positioniert wird. Aufgrund der definierten Positionierung des Filters 16 und des Arrays 18 im LOC sind LOCs austauschbar in der Analysevorrichtung 30 ohne eine erneute optische Justierung einsetzbar. Die Photolyse-Lichtquelle 31 ist bei eingelegtem LOC 10 auf die Position des Filters 16 gerichtet und die Kamera 39 ist auf die Position des Array 18, hier in der Array-Kammer 17 angeordnet, gerichtet. Bei eingelegtem LOC 10 ist der Filter 16 über dem ersten externen Temperierelement 43 angeordnet, und die Array-Kammer 17 ist über dem zweiten Temperierelement 44 angeordnet. Als Temperierelemente können Peltierelemente, Micro-Hotplates oder konvektive Heiz-/Kühl- Elemente, gegebenenfalls elektrische Widerstände, auch in Kombination verwendet werden. Die mechanische Schnittstelle ermöglicht einen geeigneten Wärmeübergang.The
Im Betrieb steuert die Steuerung 32 den Ablauf des Assay-Protokolls auf dem LOC 10. Das fluidische Netzwerk 12 wird über die fluidische Schnittstelle gesteuert. Temperaturen und Temperaturänderungen werden über die Temperierelemente 43 und 44 gesteuert. Die Detektion erfolgt mit einem Array- / Biochip und wird mittels der eine Fluoreszenz anregenden eine Array-Beleuchtungs-Lichtwelle 40 und der ein Fluoreszenzlicht beobachtenden Kamera 39, alternativ einem weiteren (nicht gezeigten) Photometer überprüft. Die Auswertung einer DNA-Analyse erfolgt durch die Beobachtung, an welchen Positionen auf einem Array 18 eine Fluoreszenz statt findet, mit der Kamera 39.In operation, the
Das LOC 10 zur Lyse von Zellen und PCR-Amplifikation hat eine gemeinsame, einen Filter 16 aufweisende, Multifunktionskammer 19 für Akkumulation von Zellen, Färbung der Zellen, Zellen-Lyse und PCR.The LOC 10 for lysis of cells and PCR amplification has a common,
- a) Positionierung der Zellen auf einem Filter;
- b) Färbung der Zellen;
- c) Zugeben einer PCR-Behandlungs-Lösung;
- d) Photolyse der Zellen; und
- e) Amplifikation von DNA der Zellen mittels PCR.
- a) positioning the cells on a filter;
- b) staining of the cells;
- c) adding a PCR treatment solution;
- d) photolysis of the cells; and
- e) Amplification of DNA of the cells by PCR.
Damit liegt die DNA der Zellen in hinreichender Menge für DNA-Untersuchungen vor. Das Verfahren ist für Gram-negative und Gram-positive Zellen geeignet.Thus, the DNA of the cells is present in sufficient quantity for DNA examinations. The method is suitable for Gram-negative and Gram-positive cells.
- f) Mischung der amplifizierten DNA mit einem Hybridisation Buffer. Dies dient der Vorbereitung für den weiteren Verfahrenschrittf) Mix the amplified DNA with a hybridization buffer. This serves as preparation for the further process step
-
g) Analyse der amplifizierten DNA. Dies betrifft die Analyse mittels einem Array, entsprechend einer Vorrichtung wie zum Beispiel in
Fig. 1 gezeigt.g) Analysis of the amplified DNA. This concerns the analysis by means of an array, corresponding to a device such as inFig. 1 shown.
In einer alternativen Ausführungsform ohne Array, entsprechend einer Vorrichtung wie zum Beispiel in
Zu den einzelnen Verfahrensschritten folgen weitere Erläuterungen, gegebenenfalls unter beispielhafter Bezugnahme auf die Analysevorrichtung 30 und das LOC 10 aus
Bezüglich der Reihenfolge der Verfahrensschritte a) und b) sind zwei alternative Ausführungsformen möglich, nämlich die Zellen vor oder nach dem Aufbringen auf dem Filter 16 zu färben.With regard to the sequence of process steps a) and b), two alternative embodiments are possible, namely to dye the cells before or after application to the
Zur Färbung der Zellen in Verfahrensschritt b) wird eine Farbstofflösung, ca. 50 µl, auf den Filter gegeben und ca. 30 s inkubiert. Anschließend wird gewaschen, z.B. zuerst mit 200 µl Ethanol und danach mit 200 µl Wasser. Als Färbereagentien können verwendet werden:
- 1) Gram-Färbung - Kristallviolett-Lösung, waschen mit 200 µl Wasser, 2
min fixieren mit 50 µl Lugolscher Lösung (Lugol's solution, Kl3-Lösung); - 2) Methylenblau-Lösung;
- 3) weitere Farbstoffe wie Malachitgrün, Safranin, Fuchsin (mit PAS-Reaktion, Periodic acid-Schiff reaction), Fuchsinschwefelige Säure für Pilze, Brillant-Grün, Methylgrün, Ethyl-Grün, Brillant-blau, Coomassie violett, etc.. Diese Farbstoffe weisen eine Ammoniumgruppe auf, typischerweise in einem Chinoiden System mit weiteren Alkyl-/Aryl-aminogruppen. Viele gehören zur Klasse der Triphenylmethan-Fabstoffe. Die Farbstoffe können auch als Feststoffe in Depots auf dem LOC 10, z.B. lyophilisiert, gelagert werden und mit Wasser in
den Filter 16 geschwemmt werden. Die gefärbten Bakterien lassen sich mit Licht mit vergleichsweise geringen Intensitäten lysieren.
- 1) Gram stain - crystal violet solution, wash with 200 μl of water, fix for 2 minutes with 50 μl of Lugol's solution (Lugol's solution, Kl 3 solution);
- 2) methylene blue solution;
- 3) other dyes such as malachite green, saffron, fuchsin (with PAS reaction, periodic acid-Schiff reaction), fuchsinschwefelige acid for mushrooms, brilliant green, methyl green, Ethyl Green, Brilliant Blue, Coomassie Violet, etc. These dyes have an ammonium group, typically in a quinonoid system with other alkyl / arylamino groups. Many belong to the class of triphenylmethane dyes. The dyes can also be stored as solids in depots on the LOC 10, for example lyophilized, and washed with water into the
filter 16. The stained bacteria can be lysed with light of comparatively low intensities.
In Verfahrensschritt c) wird der Filter mit der PCR-Behandlungs-Lösung, dem so genannten Mastermix, befüllt. Diese PCR-Behandlungs-Lösung besteht aus einer Mischung aus DNTPs (deoxynucleotide triphosphate), Primern, Polymerase und Puffer. Ferner ist in der Mischung noch eine Substanz zur Blockierung der Filteroberfläche enthalten, z.B. BSA (Bovine serum albumin), PEG (Polyethylene glycol), PPG (Polypropylene glycol). Es ist auch möglich, die erst in Verfahrensschritt e) benötigten Substanzen erst nach Verfahrensschritt d) zuzugeben.In method step c), the filter is filled with the PCR treatment solution, the so-called master mix. This PCR treatment solution consists of a mixture of DNTPs (deoxynucleotide triphosphates), primers, polymerase and buffer. Further, in the mixture, a substance for blocking the filter surface is contained, e.g. BSA (Bovine serum albumin), PEG (Polyethylene glycol), PPG (Polypropylene glycol). It is also possible to add the substances required only in process step e) only after process step d).
Die Photolyse der Zellen in Verfahrensschritt d) erfolgt bevorzugt mittels Laserlyse. Bei der Photolyse wird die DNA der Zellen freigesetzt. Der Filter, auf dem sich die angefärbten Zellen befinden, wird mit einem handelsüblichen Laser bestrahlt. Dabei wird vorzugsweise der Laserstrahl fokussiert und mit einem Mikrospiegel über den Filter geführt, wobei möglichst die gesamte Filterfläche lückenlos mit dem Laserstrahl überstrichen wird. Alternativ kann der Filter auch mit Hochenergie-LEDs, Blitzlampen oder fokussierten Lichtquellen mit hoher Energiedichte bestrahlt werden. Entscheidend ist dabei, dass die Bakterien möglichst viel Licht absorbieren, wohingegen die Matrix und die umgebende Flüssigkeit möglichst wenig Energie aufnehmen sollen. Dies wird erreicht, indem das zur Photolyse benutzte Licht im Wesentlichen in einem Wellenlängenbereich liegt, der von den gefärbten Zellen stark absorbiert wird, jedoch von Wasser schwach absorbiert wird. Die Farbe der gefärbten Zellen wird vom Farbstoff bestimmt, kann aber von der Farbe des Farbstoffs verschieden sein. Die Wellenlänge oder Wellenlängen des Photolyse-Lichts sind auf die Farbe der gefärbten Zellen abgestimmt, so dass der Absorptionskoeffizient der gefärbten Zelle ein Vielfaches des Absorptionskoeffizienten eines Fluids oder einer stationären Phase eines um die Zellen vorhanden Puffermediums, meist Wasser, beträgt. Ein Vielfaches kann beispielsweise mindestens der Faktor 2,5, zum Beispiel 10 sein. Eine hohe Energieaufnahme des Fluids oder der stationären Phase hätte eine starke schlecht kontrollierbare Temperaturerhöhung zur Folge, die zur Inaktivierung der Polymerase, zum Verdampfen des flüssigen Mediums und zum Platzen der LOCs führen kann. Die Photolyse-Lichtquelle weist vorteilhafterweise eine Wellenlänge im sichtbaren Bereich, die komplementär zur Farbe der angefärbten Zellen ist auf, z.B. 532 nm bei Rotfärbung der Zellen mit Methylenblau, so dass die Absorption durch die gefärbten Bakterien möglichst hoch ist.The photolysis of the cells in process step d) is preferably carried out by means of laser lysis. During photolysis, the DNA of the cells is released. The filter on which the stained cells are located is irradiated with a commercially available laser. In this case, the laser beam is preferably focused and guided with a micromirror on the filter, wherein as far as possible the entire filter surface is swept over completely with the laser beam. Alternatively, the filter can also be irradiated with high-energy LEDs, flash lamps or focused light sources with high energy density. The decisive factor is that the bacteria absorb as much light as possible, whereas the matrix and the surrounding liquid should absorb as little energy as possible. This is achieved by having the light used for photolysis substantially in a wavelength range which is strongly absorbed by the colored cells but weakly absorbed by water. The color of the stained cells is determined by the dye, but may be different from the color of the dye. The wavelength or wavelengths of the photolysis light are matched to the color of the stained cells, so that the absorption coefficient of the stained cell is a multiple of the absorption coefficient of a fluid or a stationary phase of a buffer medium present around the cells, usually water. A multiple may be, for example, at least the factor 2.5, for example 10. A high energy intake of the fluid or the stationary phase would result in a strong, poorly controlled increase in temperature, which may lead to inactivation of the polymerase, evaporation of the liquid medium and bursting of the LOCs. The photolysis light source advantageously has a Wavelength in the visible region which is complementary to the color of the stained cells is, for example, 532 nm in the case of red staining of the cells with methylene blue, so that the absorption by the stained bacteria is as high as possible.
Zwischen den Verfahrensschritten d) und e) findet in dieser Ausführungsform keine Aufreinigung statt. Die Verfahrensschritte a) bis d) finden alle im Filter 16 statt. Anschließend wird der Inhalt des Filters 16 in die Array-Kammer 17 gepumpt, in der anschließend die Hybridisierung und Detektion stattfindet.Between the process steps d) and e) no purification takes place in this embodiment. The process steps a) to d) all take place in the
Bei der PCR-Amplifikation der DNA in Verfahrensschritt e) wird der Filter den für die PCR üblichen thermischen Zyklen unterworfen. Bei diesen Temperaturzyklen wird die DNA wie bereits oben beschrieben vervielfältigt. Nun liegt die DNA der Zellen in hinreichender Menge für DNA-Untersuchungen vor. Das Verfahren ist für Gram-negative und Gram-positive Zellen geeignet. Anschließend kann die DNA von dem Filterelement eluiert werden. So werden z.B. aus 10 ml Urin mit 105 Zellen nach 20 Zyklen 1011 DNA Moleküle in 50 µl isoliert. Alternativ kommen andere Amplifikationen, auch isotherme, ebenso in Frage, z.B. NASBA (Nucleic Acid Sequence Based Amplification).During the PCR amplification of the DNA in method step e), the filter is subjected to the usual thermal cycles for the PCR. At these temperature cycles, the DNA is amplified as described above. Now the DNA of the cells is in sufficient quantity for DNA examinations. The method is suitable for Gram-negative and Gram-positive cells. Subsequently, the DNA can be eluted from the filter element. Thus, for example, from 10 ml of urine with 10 5 cells after 20 cycles, 10 11 DNA molecules are isolated in 50 μl. Alternatively, other amplifications, including isotherms, are also possible, for example NASBA (Nucleic Acid Sequence Based Amplification).
Nach dem Zufügen eines so genannten Hybridisation Buffer in Verfahrensschritt f) und Aufbringen auf das DNA-Array 18 mittels des fluidischen Netzwerks 12 ist die DNA für die Detektion bzw. Analyse der amplifizierten DNA in Verfahrensschritt g), mittels DNA-Array, beispielsweise Array 18 in
Das erfindungsgemäße Verfahren lässt sich einfach sowohl auf die Filter-PCR als auch auf einen voll integrierten LOC übertragen.The method according to the invention can be easily transferred both to the filter PCR and to a fully integrated LOC.
- a) Positionierung der Zellen auf einem Filter;
- b) Färbung der Zellen;
- d) Photolyse der Zellen;
- d1) Reinigung von DNA der Zellen;
- c) Zugeben einer PCR-Behandlungs-Lösung; und
- e) Amplifikation der DNA der Zellen mittels PCR.
- a) positioning the cells on a filter;
- b) staining of the cells;
- d) photolysis of the cells;
- d1) purification of DNA of the cells;
- c) adding a PCR treatment solution; and
- e) Amplification of the DNA of the cells by means of PCR.
Damit liegt die DNA der Zellen in hinreichender Menge für DNA-Untersuchungen vor. Das Verfahren ist für Gram-negative und Gram-positive Zellen geeignet.Thus, the DNA of the cells is present in sufficient quantity for DNA examinations. The method is suitable for Gram-negative and Gram-positive cells.
Vorteilhaft folgt der weitere Verfahrenschritt
- f) Mischung der amplifizierten DNA mit einem Hybridisation Buffer. Dies dient der Vorbereitung für den weiteren Verfahrenschritt
- g) Analyse der amplifizierten DNA. Die Analyse umfasst die Hybridisierung und die Detektion.
- f) Mix the amplified DNA with a hybridization buffer. This serves as preparation for the further process step
- g) Analysis of the amplified DNA. The analysis includes hybridization and detection.
In dieser Ausführungsform der vorliegenden Erfindung entsprechen die gleichnamigen Verfahrensschritte den aus der Beschreibung von
Claims (9)
- Method for the lysis of cells and PCR amplification, having the following method stepsa) positioning the cells in a chamber (19);b) staining the cells;c) adding a PCR treatment solution;d) photolysis of the cells; ande) amplification of DNA from the cells by means of PCR;wherein method steps a) and b) and also c) and d) can in each case take place in any desired order and the light used for the photolysis is substantially in a wavelength range which is strongly absorbed by the stained cells, but is poorly absorbed by water, characterized in that in method step b) the cells are stained with at least one stain from the group consisting of crystal violet solution and methylene blue solution.
- Method according to Claim 1, characterized by the further method step d1) purifying the DNA from the cells after method step d).
- Method according to Claim 1 or 2, characterized by the further method stepf) supplying a hybridization buffer to the amplified DNA.
- Method according to Claim 3, characterized by the further method stepg) analysing the amplified DNA.
- Method according to one of Claims 1 to 4, characterized in that the method steps a) to d) take place in the same volume element of an analysis chip.
- Method according to one of Claims 1 to 5, characterized in that cells, bacteria, especially Gram-positive bacteria, fungi, spores or viruses are used.
- Method according to one of Claims 1 to 6, characterized in that in method step c) the treatment solution has a mixture of dNTPs (deoxynucleotide triphosphates), primers, polymerases and buffer, and also a substance for blocking the filter surface.
- Method according to one of Claims 1 to 7, characterized in that in method step d) the photolysis of the cells is carried out by means of laser beam, high-energy LEDs, flash lamps or light sources with a high energy density.
- Method according to one of Claims 1 to 8, characterized in that a wavelength range of a light used for the photolysis is adapted to the staining of the cells such that an absorption coefficient of the stained cells is greater by a multiple than an absorption coefficient of a buffer medium present around the cells.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011007035A DE102011007035A1 (en) | 2011-04-08 | 2011-04-08 | Method, LOC and analyzer for cell lysis and PCR amplification |
PCT/EP2012/052072 WO2012136400A1 (en) | 2011-04-08 | 2012-02-08 | Method, loc and analysis device for the lysis of cells and pcr amplification |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2694672A1 EP2694672A1 (en) | 2014-02-12 |
EP2694672B1 true EP2694672B1 (en) | 2018-09-12 |
Family
ID=45607230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12704033.5A Active EP2694672B1 (en) | 2011-04-08 | 2012-02-08 | Method for the lysis of cells and pcr amplification |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2694672B1 (en) |
DE (1) | DE102011007035A1 (en) |
WO (1) | WO2012136400A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102013203655B4 (en) * | 2013-03-04 | 2023-03-23 | Robert Bosch Gmbh | Method and device for the selective lysis of cellular particles |
DE102014207774B4 (en) * | 2014-04-25 | 2015-12-31 | Robert Bosch Gmbh | Method and device for purifying biological molecules |
EP3338889A1 (en) | 2016-12-23 | 2018-06-27 | IMEC vzw | Combined extraction and pcr systems |
DE102017123919A1 (en) | 2017-10-13 | 2019-04-18 | Gna Biosolutions Gmbh | Method and apparatus for lysing microorganisms |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028379A (en) | 1989-12-20 | 1991-07-02 | General Electric Company | Fuel handling system for nuclear reactor plants |
US6815209B2 (en) * | 2001-11-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Laser-induced cell lysis system |
KR101157175B1 (en) * | 2005-12-14 | 2012-07-03 | 삼성전자주식회사 | Microfluidic device and method for concentration and lysis of cells or viruses |
KR100813271B1 (en) * | 2006-11-09 | 2008-03-13 | 삼성전자주식회사 | Method and apparatus for disrupting cell or virus and amplifying nucleic acids using gold nanorod |
-
2011
- 2011-04-08 DE DE102011007035A patent/DE102011007035A1/en not_active Withdrawn
-
2012
- 2012-02-08 EP EP12704033.5A patent/EP2694672B1/en active Active
- 2012-02-08 WO PCT/EP2012/052072 patent/WO2012136400A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
WO2012136400A1 (en) | 2012-10-11 |
DE102011007035A1 (en) | 2012-10-11 |
EP2694672A1 (en) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Enger et al. | Optical tweezers applied to a microfluidic system | |
EP2299257B1 (en) | Device and method for detecting molecular interactions | |
JP5063616B2 (en) | Microfluidic device | |
EP1054735B1 (en) | Miniaturized temperature-zone flow reactor | |
EP2694672B1 (en) | Method for the lysis of cells and pcr amplification | |
EP1780290A2 (en) | Apparatus for amplifying nucleic acids | |
JP2005506541A (en) | Sample preparation integrated chip | |
EP2152913A2 (en) | Detection device for detecting biological microparticles such as bacteria, viruses, spores, pollen or biological toxins, and detection method | |
DE112015007082B4 (en) | Cell analysis device, device and a cell analysis method using the same | |
WO2015156738A1 (en) | Microfluidic device | |
DE102014209188B4 (en) | Apparatus and method for processing a biological sample and analysis system for analyzing a biological sample | |
DE102014105437A1 (en) | Microfluidic module and cassette for immunological and molecular diagnostics in an automated analyzer | |
WO2005107949A1 (en) | Method and apparatus for creating an analysis arrangement comprising discrete, separate test zones used for performing biological, biochemical, or chemical analyses | |
EP2836302B1 (en) | Method and device for targeted process control in a microfluidic processor having integrated active elements | |
EP1123980B1 (en) | System for simple nucleic acid analysis | |
EP2555872B1 (en) | Device for detecting nucleic acids | |
Maruyama et al. | Immobilization of individual cells by local photo-polymerization on a chip | |
DE102005059535A1 (en) | Device and method for carrying out a nucleic acid test, and method for producing such a device | |
Chou | Microfabricated Devices for Rapid DNA Diagnostics | |
EP3283879B1 (en) | Method for detecting one or more analytes in a sample, said detection being delimited by a reaction chamber | |
EP3063525B1 (en) | Improved device and method for reactions between a solid and a liquid phase | |
WO2001070399A1 (en) | Microhybridisation chamber | |
DE102014200468A1 (en) | Microfluidic system and method for preparing and analyzing a sample of biological material containing cells | |
DE102014200467A1 (en) | Microfluidic system and method for analyzing a sample of biological material | |
DE112021004322T5 (en) | Sensor system and method for detecting dielectric particles from biological materials in fluids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140903 |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 502012013418 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12Q0001680000 Ipc: B01L0003000000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: B01L 3/00 20060101AFI20180419BHEP Ipc: B01L 7/00 20060101ALI20180419BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180529 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 502012013418 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1039906 Country of ref document: AT Kind code of ref document: T Effective date: 20181015 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181212 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181213 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190112 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190112 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 502012013418 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
26N | No opposition filed |
Effective date: 20190613 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190208 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190208 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 1039906 Country of ref document: AT Kind code of ref document: T Effective date: 20190208 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190208 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20200221 Year of fee payment: 9 Ref country code: NL Payment date: 20200220 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120208 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20210301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210208 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20220221 Year of fee payment: 11 Ref country code: CH Payment date: 20220221 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20220221 Year of fee payment: 11 Ref country code: BE Payment date: 20220216 Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180912 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230426 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230228 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230208 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230208 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230208 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 |